These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32574395)

  • 1. Thromboembolic and bleeding outcomes in patients with atrial fibrillation and valvular heart disease: A descriptive nationwide cohort study.
    Melgaard L; Jensen M; Overvad TF; Larsen TB; Lip GYH; Nielsen PB
    Int J Clin Pract; 2020 Oct; 74(10):e13589. PubMed ID: 32574395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study.
    Lip GYH; Jensen M; Melgaard L; Skjøth F; Nielsen PB; Larsen TB
    Europace; 2019 Jan; 21(1):33-40. PubMed ID: 29986001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thromboembolism and Major Bleeding in Patients with Atrial Fibrillation and EHRA Type 2 Valvular Heart Disease: The Jordan Atrial Fibrillation (JoFib) Study.
    Al-Najar M; Al-Nusair M; Alrabadi N; Alawaisheh I; Alawaisheh T; Jarrah M; Alzoubi KH; Njem S; Hamoudeh A
    Vasc Health Risk Manag; 2023; 19():145-155. PubMed ID: 36968249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification.
    Bisson A; Bodin A; Clementy N; Bernard A; Babuty D; Lip GYH; Fauchier L
    Int J Cardiol; 2018 Jun; 260():93-98. PubMed ID: 29540261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
    Lip GYH; Collet JP; Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B;
    Europace; 2017 Nov; 19(11):1757-1758. PubMed ID: 29096024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thromboembolic Risk in Nonanticoagulated Patients With Atrial Fibrillation and Valvular Heart Disease.
    Melgaard L; Overvad TF; Jensen M; Lip GYH; Larsen TB; Nielsen PB
    JACC Clin Electrophysiol; 2020 Dec; 6(13):1672-1682. PubMed ID: 33334446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
    Lip GYH; Collet JP; de Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B
    Thromb Haemost; 2017 Dec; 117(12):2215-2236. PubMed ID: 29212110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease.
    Briasoulis A; Inampudi C; Akintoye E; Alvarez P; Panaich S; Vaughan-Sarrazin M
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29622591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation).
    Thomas KL; Jackson LR; Shrader P; Ansell J; Fonarow GC; Gersh B; Kowey PR; Mahaffey KW; Singer DE; Thomas L; Piccini JP; Peterson ED
    J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29273635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboembolism and bleeding complications in anticoagulated patients with atrial fibrillation and native aortic or mitral valvular heart disease: a descriptive nationwide cohort study.
    Melgaard L; Overvad TF; Jensen M; Lip GYH; Larsen TB; Nielsen PB
    Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f101-f110. PubMed ID: 32003787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Valvular Heart Disease on Mortality, Thromboembolic and Cardiac Events in Japanese Patients With Atrial Fibrillation　- The Fushimi AF Registry.
    Doi K; Ogawa H; Ishigami K; Ikeda S; Aono Y; Hamatani Y; Fujino A; An Y; Ishii M; Iguchi M; Masunaga N; Esato M; Tsuji H; Wada H; Hasegawa K; Abe M; Akao M;
    Circ J; 2020 Apr; 84(5):714-722. PubMed ID: 32213725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel oral anticoagulants and valvular atrial fibrillation: are they always contraindicated?
    Di Pasquale G; Zagnoni S; Riva L
    Intern Emerg Med; 2015 Feb; 10(1):21-4. PubMed ID: 25589164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation for valvular heart disease in community-based practice.
    Rose AJ; Ozonoff A; Henault LE; Hylek EM
    Thromb Haemost; 2010 Feb; 103(2):329-37. PubMed ID: 20024499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
    De Caterina R; Renda G; Carnicelli AP; Nordio F; Trevisan M; Mercuri MF; Ruff CT; Antman EM; Braunwald E; Giugliano RP
    J Am Coll Cardiol; 2017 Mar; 69(11):1372-1382. PubMed ID: 28302288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis.
    Caldeira D; David C; Costa J; Ferreira JJ; Pinto FJ
    Eur Heart J Cardiovasc Pharmacother; 2018 Apr; 4(2):111-118. PubMed ID: 28950374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and outcomes of atrial fibrillation patients with or without specific symptoms: results from the PREFER in AF registry.
    Bakhai A; Darius H; De Caterina R; Smart A; Le Heuzey JY; Schilling RJ; Zamorano JL; Shah M; Bramlage P; Kirchhof P
    Eur Heart J Qual Care Clin Outcomes; 2016 Oct; 2(4):299-305. PubMed ID: 29474715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct oral anticoagulant use in nonvalvular atrial fibrillation with valvular heart disease: a systematic review.
    Owens RE; Kabra R; Oliphant CS
    Clin Cardiol; 2017 Jun; 40(6):407-412. PubMed ID: 28004413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease.
    Renda G; Ricci F; Giugliano RP; De Caterina R
    J Am Coll Cardiol; 2017 Mar; 69(11):1363-1371. PubMed ID: 28302287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.